Please wait while the transcript is being prepared...
0:00
Hello, I'm Snejana Krassova.
I'm a medical doctor and
a former Vice President and Head of
Medical Affairs at Bayer Hematology.
I'm presenting today on
Factor VII Deficiency.
0:14
We will delve into the
background, epidemiology,
review the clinical
picture, treatment options,
and a little bit on
patient education.
0:25
Factor VII is a vitamin
K-dependent clotting factor and
it's very crucial in
triggering blood coagulation.
There are two factor
VII Deficiencies:
inherited and acquired.
Today we're focusing on
inherited factor VII deficiency.
Inherited deficiency,
this is an autosomal recessive
disorder for factor VII gene.
Factor VII gene is
located on chromosome 13.
1% of activated factor VII
circulates in its active form
and its half-life is 3.5 hours.
It's the most common amongst
the rare coagulation disorders.
1:03
When we look at the
coagulation pathways,
this is an issue of
the extrinsic system.
The extrinsic pathway
is where you need
activated factor VIIa to create
a thrombin burst in the
coagulation cascade.
It needs to have a
co-factor, tissue factor,
that plays a role
when we do essays,
and substrate factor
VIIa-tissue factor complex is
absolutely necessary
further downstream,
to activate factor X and IX.
Obviously, deficiencies
of factor VII will affect
factor VIIa and thrombin
burst down the road.
Therefore, it actually affects
the whole coagulation
cascade and
that's why factor VII
deficiency does present
a clinical challenge and
needs to be managed
in certain patients,
which we'll go into right
now on epidemiology.
